Home›Trial›NCT06680037
🔬NCT06680037Phase 1RECRUITING

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Study Summary

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).

Conditions
B-cell Mediated Autoimmune Disorders
Interventions / Drugs
Azercabtagene zapreleucel (azer-cel)
View on ClinicalTrials.gov ↗
Sponsor
TGTX
TG Therapeutics
Oncology
D36/100
Study Details
Enrollment32 participants
Primary Completion—
Lead SponsorTG Therapeutics, Inc.
Data Retrieved2026-04-11 04:29:09.137990+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.